- Home
- WEA vs ALEC Comparison
WEA vs ALEC Comparison
Compare WEA & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- ALEC
- Stock Information
- Founded
- WEA 2002
- ALEC 2013
- Country
- WEA United States
- ALEC United States
- Employees
- WEA N/A
- ALEC N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- ALEC Health Care
- Exchange
- WEA Nasdaq
- ALEC Nasdaq
- Market Cap
- WEA 129.9M
- ALEC 124.0M
- IPO Year
- WEA N/A
- ALEC 2019
- Fundamental
- Price
- WEA $10.96
- ALEC $3.04
- Analyst Decision
- WEA
- ALEC Buy
- Analyst Count
- WEA 0
- ALEC 7
- Target Price
- WEA N/A
- ALEC $4.50
- AVG Volume (30 Days)
- WEA 46.1K
- ALEC 1.1M
- Earning Date
- WEA 01-01-0001
- ALEC 11-05-2025
- Dividend Yield
- WEA 7.87%
- ALEC N/A
- EPS Growth
- WEA N/A
- ALEC N/A
- EPS
- WEA N/A
- ALEC N/A
- Revenue
- WEA N/A
- ALEC $81,130,000.00
- Revenue This Year
- WEA N/A
- ALEC N/A
- Revenue Next Year
- WEA N/A
- ALEC $290.64
- P/E Ratio
- WEA N/A
- ALEC N/A
- Revenue Growth
- WEA N/A
- ALEC 46.77
- 52 Week Low
- WEA $9.60
- ALEC $0.87
- 52 Week High
- WEA $11.29
- ALEC $6.14
- Technical
- Relative Strength Index (RSI)
- WEA 35.29
- ALEC 53.40
- Support Level
- WEA $10.96
- ALEC $2.87
- Resistance Level
- WEA $11.15
- ALEC $3.40
- Average True Range (ATR)
- WEA 0.15
- ALEC 0.21
- MACD
- WEA -0.04
- ALEC -0.03
- Stochastic Oscillator
- WEA 22.80
- ALEC 44.74
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.